These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 8500877

  • 21. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice.
    Mitra S, Barman S, Nag D, Sinha R, Saha DR, Koley H.
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):240-50. PubMed ID: 22762732
    [Abstract] [Full Text] [Related]

  • 22. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN, Osorio M, Takeda K, Stibitz S, Kopecko DJ.
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [Abstract] [Full Text] [Related]

  • 23. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
    Simon JK, Wahid R, Maciel M, Picking WL, Kotloff KL, Levine MM, Sztein MB.
    Vaccine; 2009 Jan 22; 27(4):565-72. PubMed ID: 19022324
    [Abstract] [Full Text] [Related]

  • 24. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B, Sharma D, Padh H, Desai P.
    Vaccine; 2019 May 21; 37(23):3097-3105. PubMed ID: 31047673
    [Abstract] [Full Text] [Related]

  • 25. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG.
    EBioMedicine; 2021 Apr 21; 66():103310. PubMed ID: 33862589
    [Abstract] [Full Text] [Related]

  • 26. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S.
    Pediatr Infect Dis J; 1995 Oct 21; 14(10):859-65. PubMed ID: 8584312
    [Abstract] [Full Text] [Related]

  • 27. Technological aspect of the production of live dysentery vaccines for oral administration.
    Denchev V, Nenkov P, Vitanov T, Sumerska T, Marinova S, Vassilev T, Panova I, Bratoeva M, Linde K.
    Acta Microbiol Hung; 1991 Oct 21; 38(2):121-6. PubMed ID: 1805499
    [Abstract] [Full Text] [Related]

  • 28. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.
    Bernardini ML, Arondel J, Martini I, Aidara A, Sansonetti PJ.
    Infect Immun; 2001 Feb 21; 69(2):1072-83. PubMed ID: 11160004
    [Abstract] [Full Text] [Related]

  • 29. [Live shigella flexneri 2a and shigella sonnei vaccines (author's transl)].
    Belaia IuA, Gekker VD, Kuz'min SN, Sergeeva NS.
    Acta Microbiol Acad Sci Hung; 1974 Feb 21; 21(1-2):63-9. PubMed ID: 4216253
    [No Abstract] [Full Text] [Related]

  • 30. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
    Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF.
    Vaccine; 2013 Jun 19; 31(28):2919-29. PubMed ID: 23644075
    [Abstract] [Full Text] [Related]

  • 31. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.
    Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW.
    mSphere; 2018 Jun 19; 3(2):. PubMed ID: 29600284
    [Abstract] [Full Text] [Related]

  • 32. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.
    Vaccine; 2007 Mar 08; 25(12):2269-78. PubMed ID: 17229494
    [Abstract] [Full Text] [Related]

  • 33. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
    Noriega FR, Losonsky G, Wang JY, Formal SB, Levine MM.
    Infect Immun; 1996 Jan 08; 64(1):23-7. PubMed ID: 8557344
    [Abstract] [Full Text] [Related]

  • 34. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.
    Hartman AB, Van de Verg LL, Collins HH, Tang DB, Bendiuk NO, Taylor DN, Powell CJ.
    Infect Immun; 1994 Feb 08; 62(2):412-20. PubMed ID: 7507892
    [Abstract] [Full Text] [Related]

  • 35. Shigellosis: the current status of vaccine development.
    Kweon MN.
    Curr Opin Infect Dis; 2008 Jun 08; 21(3):313-8. PubMed ID: 18448978
    [Abstract] [Full Text] [Related]

  • 36. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM.
    Infect Immun; 2001 May 08; 69(5):3150-8. PubMed ID: 11292735
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.
    Mallett CP, VanDeVerg L, Collins HH, Hale TL.
    Vaccine; 1993 May 08; 11(2):190-6. PubMed ID: 8438617
    [Abstract] [Full Text] [Related]

  • 38. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA, Frenck RW, Dickey M, Suvarnapunya AE, Chandrasekaran L, Weerts HP, Heaney CD, McNeal M, Detizio K, Parker S, Hoeper A, Bourgeois AL, Porter CK, Venkatesan MM, Kaminski RW.
    mSphere; 2020 Sep 23; 5(5):. PubMed ID: 32968012
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.
    Vaccine; 1995 Apr 23; 13(5):495-502. PubMed ID: 7639017
    [Abstract] [Full Text] [Related]

  • 40. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.